Company Encyclopedia
View More
name
Mira Pharmaceuticals
MIRA.US
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
4.513 T
MIRA.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    MIRA Pharmaceuticals (NASDAQ:MIRA) Rating Lowered to Sell at Wall Street Zen

    Wall Street Zen downgraded MIRA Pharmaceuticals (NASDAQ:MIRA) from "hold" to "sell". Weiss Ratings also reiterated a "sell" rating. MIRA's stock opened at $1.39 with a market cap of $58.21 million. Analysts expect a -0.6 EPS for the fiscal year. Institutional investors have adjusted their holdings, with 35.16% owned by them. MIRA operates as a pre-clinical-stage pharmaceutical company focusing on neurologic disorders. Despite the sell rating, analysts suggest other stocks as better investments.

    Market Beat·
    US
    MIRA
    -1.35%
    Market Beat·
    US
    MIRA
    -1.35%

    Mira Pharmaceuticals | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    MIRA
    -1.35%
    LB filings·
    US
    MIRA
    -1.35%

    Mira Pharmaceuticals Inc - Initiates Phase 1 Study Of Ketamir-2 - SEC Filing

    Mira Pharmaceuticals Inc :MIRA PHARMACEUTICALS INC - INITIATES PHASE 1 STUDY OF KETAMIR-2 - SEC FILING

    Reuters·
    US
    MIRA
    -1.35%
    Reuters·
    US
    MIRA
    -1.35%

    MIRA Pharmaceuticals Advances Ketamir-2 Clinical Trials

    MIRA Pharmaceuticals has initiated the multiple ascending dose phase of its Phase 1 clinical trial for Ketamir-2, aimed at treating chemotherapy-induced peripheral neuropathy (CIPN). This is notable as there are no FDA-approved treatments for CIPN. Ketamir-2 has shown promising preclinical results and may qualify for FDA Fast Track designation. MIRA focuses on developing therapies for unmet medical needs, with Ketamir-2 being an oral analog of ketamine for neuropathic pain. Current market cap is $27.65M with a buy signal in technical sentiment.

    Tip Ranks·
    US
    MIRA
    -1.35%
    Tip Ranks·
    US
    MIRA
    -1.35%

    Mira Pharmaceuticals Raises $3.8 Million Through Block Sale of 1.75 Million Shares at 66% Premium

    Mira Pharmaceuticals Inc. has raised $3.84 million by selling 1,751,000 shares at $2.19 each, a 66% premium over the previous closing price. The block sale was facilitated by Rodman & Renshaw through the StockBlock platform, with no warrants included in the offering. This transaction involved multiple institutional investors and was reported on October 16, 2025.

    Reuters·
    US
    MIRA
    -1.35%
    Reuters·
    US
    MIRA
    -1.35%
    © 2025 Longbridge｜Disclaimer